10-Q: Precision BioSciences Reports Q1 2026 Financials

Precision BioSciences Inc. reported its first quarter 2026 financial results, highlighting significant revenue growth driven by collaboration agreements and continued investment in its lead gene editing programs.

Summary

• Precision BioSciences reported revenue of $10.8 million for the three months ended March 31, 2026, a substantial increase from $0.03 million in the same period of 2025.
• The company's net loss for the quarter was $18.4 million, an improvement from a net loss of $20.6 million in Q1 2025.
• Research and development expenses decreased slightly to $13.1 million from $13.6 million year-over-year, primarily due to a reduction in platform development costs, offset by increased spending on PBGENE-DMD and PBGENE-HBV programs.
• General and administrative expenses also decreased to $6.8 million from $8.6 million, mainly due to lower employee-related costs.
• As of March 31, 2026, the company had $99.4 million in cash and cash equivalents, and $26.5 million in restricted cash.
• The company anticipates its current cash and cash equivalents will be sufficient to fund operations through 2028.
• PBGENE-HBV program is advancing with clinical data expected at conferences and expansion into France and Romania.
• PBGENE-DMD program is progressing with the FUNCTION-DMD Phase 1/2 clinical trial activating its first site and enrolling patients; received FDA Fast Track designation in March 2026.
• The company recognized $6.8 million in revenue under the TG License Agreement during the quarter.
• A legacy ARCUS gene editing research and license agreement milestone contributed $4.0 million in revenue.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with strong revenue growth from collaborations and positive clinical trial updates, but still facing significant financial risks due to ongoing losses and the need for future capital.

Positives

• Significant revenue increase to $10.8 million in Q1 2026 from $0.03 million in Q1 2025, driven by collaboration agreements.
• Net loss narrowed to $18.4 million from $20.6 million in the prior year's quarter.
• PBGENE-DMD received FDA Fast Track designation in March 2026.
• PBGENE-HBV program is expanding into France and Romania.
• The company expects its cash runway to be sufficient through 2028.
• The company recognized $6.8 million in revenue from the TG License Agreement and $4.0 million from an agriculture collaboration milestone.

Negatives

• The company continues to incur significant operating losses and has an accumulated deficit of $546.6 million as of March 31, 2026.
• The fair value of warrant liabilities increased, resulting in a non-cash loss of $7.1 million for the quarter.
• The company's cash and cash equivalents decreased from $110.8 million at the end of 2025 to $99.4 million at the end of Q1 2026.
• The company's reliance on future financings to fund operations presents a significant risk.

Risks

• The company has incurred significant operating losses since inception and expects to continue to incur losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• The company requires substantial additional funding and may be forced to delay, reduce, or eliminate research programs if unable to raise sufficient capital.
• ARCUS is a novel technology, making product candidate development time, cost, and success difficult to predict.
• The company has a limited operating history, making it difficult to evaluate future prospects.
• Adverse public perception of genome editing technology could negatively impact developmental progress or commercial success.
• Significant competition exists in the biopharmaceutical and biotechnology fields, with competitors potentially developing safer or more effective treatments.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• The regulatory landscape for therapeutic product candidates is rigorous, complex, and subject to change.
• Clinical trials are expensive, time-consuming, and have uncertain outcomes.
• Manufacturing problems for novel product candidates could lead to development and commercialization delays.
• The company's future success depends on its key executives and qualified personnel.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.

Future Outlook

The company believes its existing cash and cash equivalents, fiscal and operating discipline, and ATM facility availability will be sufficient to fund operations through 2028, including PBGENE-HBV and PBGENE-DMD data milestones. However, it acknowledges the need for additional capital and the risks associated with obtaining it.

Management Comments

• The company is focused on leveraging its ARCUS genome editing platform to advance a new potential class of gene editing programs.
• PBGENE-HBV is the first in vivo gene editing approach to prospectively employ repeat administrations of lipid nanoparticle (LNP).
• PBGENE-DMD is designed to potentially improve function for approximately 60% of patients afflicted with DMD by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene.
• The company expects to share further clinical data from the PBGENE-HBV program at hepatitis-focused medical conferences throughout 2026.
• The company expects its research and development expenses will increase over the long term as it progresses product candidates through development.

Industry Context

StockSavvy.ai notes that Precision BioSciences' Q1 2026 results reflect the ongoing trend of increased revenue recognition from collaboration milestones in the gene editing and biotechnology sector. The company's focus on in vivo therapies for genetic and infectious diseases aligns with industry efforts to develop more targeted and potentially curative treatments.

Comparison to Industry Standards

• The revenue generated from the TG License Agreement ($6.8 million) and the agriculture milestone ($4.0 million) represents a significant step towards commercialization, though still modest compared to established biopharmaceutical companies with approved products.
• The company's R&D spend of $13.1 million is in line with early-stage biotechnology companies investing heavily in pipeline development.
• The net loss of $18.4 million is typical for companies at this stage of development, prioritizing pipeline advancement over immediate profitability.

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Stakeholder Impact

• Shareholders may see potential dilution if the company raises additional capital through equity financings.
• The company's continued progress in its lead programs (PBGENE-HBV and PBGENE-DMD) is positive for investors seeking growth in the gene editing sector.
• The company's reliance on future funding could impact its ability to execute its long-term strategy, affecting all stakeholders.

Next Steps

• Share further clinical data from the PBGENE-HBV program at hepatitis-focused medical conferences throughout 2026.
• Initiate patient screening in France and Romania for the ELIMINATE-B trial in Q2 2026.
• Continue patient enrollment for the FUNCTION-DMD Phase 1/2 clinical trial.
• Continue to advance development of PBGENE-HBV and PBGENE-DMD programs.

Key Dates

Recommendation

The company shows promising clinical development and significant revenue growth from collaborations, but the substantial accumulated deficit and ongoing need for capital present considerable risk. Investors should monitor clinical trial progress and future financing activities closely.

Keywords

Precision BioSciences, Form 10-Q, Gene Editing, ARCUS Platform, PBGENE-HBV, PBGENE-DMD, Hepatitis B, Duchenne Muscular Dystrophy, Clinical Trials, Financial Results, SEC Filing, Biotechnology